Challenges: The pharmacological manipulation of members of the transforming growth factor beta family in the chemoprevention of breast cancer

BioEssays

Volumn 15, Issue 1, 1993, Pages 71-74

  Dickens, Tracey‐Anne ^a   Colletta, Anthony A ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GESTAGEN; RETINOID; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

BIOSYNTHESIS; BREAST TUMOR; HUMAN; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; HUMAN; PROGESTATIONAL HORMONES; RETINOIDS; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

EID: 0027348425     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.950150111     Document Type: Article

References (46)

1. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
2. Prospects for the chemoprevention of breast cancer
3. The steroid and thyroid hormone receptor superfamily
4. Transforming growth factor beta: biochemistry and roles in embryogenisis, tissue repair and remodeling and carcinogenesis
5. Trans forming growth factors and control of neoplastic growth
6. Human transforming growth factor‐β complementary DNA sequence and expression in normal and transformed cells
7. Comparison of the biological actions of TGF‐β1 and TGF‐β2: differential activity in endothelial cells
8. Latent high molecular weight complex of transforming growth factor beta;1
9. Receptors for the TGF‐β family
10. Approaches to prevention of epithelial cancer during the preneoplastic period
11. Suppression of carcinogenesis; a role for TGFbeta; and related molecules in the prevention of cancer
12. Hepatic processing of transforming growth factor beta; in the rat
13. Recombinant latent transforming growth factor‐β1 has a longer plasma half life in rats than active transforming growth factor‐β1 and a different tissue distribution
14. The transforming growth factor betas
15. Pharmacokinetics of TGFbeta; with emphasis on effects on liver and gut
16. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes
17. Controled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer
18. Adjuvant tamoxifen in the management of breast cancer
19. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for the prevention of breast cancer
20. The oestrogen receptor binds tightly to its oestrogen response elements as a ligand‐induced homodimer
21. The human oestrogen receptor has two independent non‐acidic transcription activation functions
22. Characterisation and colocalisation of steroid binding and dimerisation activities in the mouse oestrogen receptor
23. High affinity antioestrogen binding site distinct from oestrogen receptor
24. Variation of inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen; correlations with cytotoxicity
25. Modes of inhibition of protein kinase C by triphenylacrylonitrile antioestrogens
26. Evidence that TGFbeta; is a hormonally regulated negative growth factor in human breat cancer cells
27. The effects of oestrogens and antioestrogens on hormone‐responsive Human Breast Cancer in long term tissue culture
28. Effects of oestrogens and antioestrogens on growth of human breast cancer cells in nude mice
29. Evidence for the induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment
30. Oral contraceptive use and breast cancer risk in young women
31. The growth inhibition of human breast cancer cells by a novel synthetic progestin involves the induction of transforming growth factor beta
32. Adjuvant therapy for operable breast cancer with medroxyprogestrone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients
33. Clinical results with megestrol acetate in patients with advanced carcinoma of the breast
34. Depot medroxy‐progesterone (Depo‐Provera) and risk of breast cancer
35. Chemoprevention of cancer with retinoids
36. N‐(4‐Hydroxyphenyl) retinamide, a new retinoid for prevention of breast cancer in the rat
37. Retinoids
38. Role of retinoids in differentiation and carcinogenesis
39. Prevention of primary prostate cancer in lobund‐wistar rats by N‐(4‐Hydroxyphenyl)retinamide
40. Retinoids in cancer therapy
41. Long term tolerability of fenretinide (4‐HPR) in breast cancer patients
42. Complex regulation of TGFbeta; expression by retinoic acid in the vitamin A deficient rat
43. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling
44. Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats
45. Overview from the International Conference on long‐term tamoxifen therapy for breast cancer